These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 12200368)
1. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Bougie DW; Wilker PR; Wuitschick ED; Curtis BR; Malik M; Levine S; Lind RN; Pereira J; Aster RH Blood; 2002 Sep; 100(6):2071-6. PubMed ID: 12200368 [TBL] [Abstract][Full Text] [Related]
2. Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors. Aster RH; Curtis BR; Bougie DW; Dunkley S; Greinacher A; Warkentin TE; Chong BH; J Thromb Haemost; 2006 Mar; 4(3):678-9. PubMed ID: 16460451 [No Abstract] [Full Text] [Related]
9. Abciximab pharmacodynamics are unaffected by antecedent therapy with other GPIIb/IIIa antagonists in non-human primates. Nakada MT; Sassoli PM; Tam SH; Nedelman MA; Jordan RE; Kereiakes DJ J Thromb Thrombolysis; 2002 Aug; 14(1):15-24. PubMed ID: 12652146 [TBL] [Abstract][Full Text] [Related]
10. Eptifibatide-induced acute profound thrombocytopenia: a case report. Graidis C; Golias C; Dimitriadis D; Dimitriadis G; Bitsis T; Dimitrelos I; Tsiakou A; Charalabopoulos K BMC Res Notes; 2014 Feb; 7():107. PubMed ID: 24564943 [TBL] [Abstract][Full Text] [Related]
11. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
12. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI. Puri A; Bansal A; Narain VS; Sethi R; Dwivedi SK; Puri VK; Saran RK Indian Heart J; 2013; 65(2):152-7. PubMed ID: 23647894 [TBL] [Abstract][Full Text] [Related]
13. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Marciniak SJ; Jordan RE; Mascelli MA Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828 [TBL] [Abstract][Full Text] [Related]